Softgel Capsules Market Size to Rake USD 17.19 Bn by 2033

The global softgel capsules market size was valued at USD 8.71 billion in 2023 and is predicted to hit around USD 17.19 billion by 2033 with a CAGR of 7.03% from 2024 to 2033.

Softgel capsules are a popular dosage form in the pharmaceutical, nutraceutical, and cosmetic industries. These capsules are made from a gelatin shell containing a liquid or semi-solid fill material. Softgel capsules offer several advantages over other dosage forms, including ease of swallowing, enhanced bioavailability of active ingredients, and better stability for sensitive compounds. The global softgel capsules market has witnessed significant growth in recent years, driven by increasing consumer demand for convenient and easy-to-administer medications and supplements.

Softgel Capsules Market Size 2024 to 2033

Key Points

North America led the market with the largest market share of 43% in 2023.
By type, the gelatin-based/animal-based segment has accounted biggest market share in 2023.
By application, the vitamins and dietary supplements segment held the largest share of the market in 2023.
By end-use, the nutraceutical companies segment has contributed more than 38% of market share in 2023.

Get a Sample: https://www.precedenceresearch.com/sample/3929

Growth Factors

Several factors contribute to the growth of the softgel capsules market. One of the primary drivers is the rising prevalence of chronic diseases worldwide, leading to increased demand for pharmaceutical products encapsulated in softgel form. Additionally, the growing trend of self-medication and preventive healthcare has boosted the demand for over-the-counter softgel supplements, vitamins, and dietary supplements. Furthermore, technological advancements in softgel manufacturing processes, such as improved formulation techniques and automated production systems, have led to enhanced product quality and cost efficiency, further fueling market growth.

Region-wise Analysis:

The softgel capsules market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe dominate the market, driven by the presence of established pharmaceutical and nutraceutical industries, high healthcare expenditure, and increasing consumer awareness about health and wellness. The Asia Pacific region is witnessing rapid growth due to the expanding pharmaceutical and dietary supplement industries, rising disposable income, and growing urbanization. Moreover, emerging economies in Latin America and the Middle East and Africa offer lucrative opportunities for market expansion due to improving healthcare infrastructure and rising demand for quality healthcare products.

Softgel Capsules Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2033	CAGR of 7.03%
Global Market Size in 2023	USD 8.71 Billion
Global Market Size by 2033	USD 17.19 Billion
U.S. Market Size in 2023	USD 2.81 Billion
U.S. Market Size by 2033	USD 5.54 Billion
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Type, By Application, and By End-use
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Softgel Capsules Market Dynamics

Drivers of Market Growth:

Several key drivers are propelling the growth of the softgel capsules market. One significant factor is the increasing preference for softgel capsules among consumers due to their ease of swallowing, better taste masking, and improved stability of active ingredients. Additionally, the growing adoption of softgel capsules by pharmaceutical companies for the encapsulation of poorly water-soluble drugs has boosted market growth. Moreover, the expanding geriatric population worldwide, coupled with the rising incidence of lifestyle-related diseases, has fueled the demand for softgel formulations containing vitamins, minerals, and other health supplements.

Restraints:

Despite the overall growth trajectory, the softgel capsules market faces certain challenges that may hinder its expansion. One of the primary restraints is the stringent regulatory requirements imposed by regulatory authorities regarding the safety, quality, and efficacy of softgel products. Compliance with these regulations adds to the production costs and time-to-market, thereby impacting profit margins. Additionally, fluctuations in raw material prices, particularly gelatin, which is derived from animal sources, pose a challenge to manufacturers. Moreover, concerns regarding the environmental sustainability of gelatin-based capsules have led to increased interest in plant-based alternatives, which could potentially disrupt the market dynamics.

Opportunities for Market Expansion:

Despite the challenges, the softgel capsules market presents several opportunities for growth and innovation. One promising opportunity lies in the development of novel formulations and delivery systems to cater to specific patient needs and preferences. For instance, the introduction of controlled-release softgel capsules for prolonged drug release offers advantages in terms of improved patient compliance and therapeutic efficacy. Moreover, expanding market penetration in emerging economies, coupled with strategic collaborations and partnerships with local distributors and manufacturers, can unlock new growth avenues. Furthermore, the growing trend of personalized medicine and the increasing focus on preventive healthcare present opportunities for the development of customized softgel formulations tailored to individual patient requirements.

Recent Developments

In May 2022, the launch of SOLFEROL Softgel Capsules, a line of reimbursed vitamin D3 medications, for the treatment of vitamin D insufficiency was announced by Windzor Pharma Ireland Ltd. This product has the broadest array of presentations available on the market, with two distinct strengths: 400 IU for treating expectant and nursing mothers and 20,000 IU for those with severe vitamin D3 deficiency.
In December 2023, Amneal Pharmaceuticals and Strides Pharma Science Limited announced the launch of Icosapent ethyl acid soft gel capsules, a product that refers VASCEPA. Strides, a multinational pharmaceutical producer, has granted an in-license for the medicine, which Amneal will begin marketing in the fourth quarter of 2023. An ethyl ester of eicosapentaenoic acid (EPA), isicosapent ethyl acid soft gel capsules, 0.5g and 1g, are recommended as a dietary supplement to lower triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.